Full Press Release Details
Melbourne (Australia) | 23 August 2023
To watch the investor webcast click h ere
Telix 2023 Half-Year Results: Revenue and Earnings Growth Marks Transition to a Sustainable Commercial-Stage Company
Telix today announces its financial results for the half-year ended 30 June 2023. All figures are in AUD$ unless otherwise stated. [1]
Dr Christian Behrenbruch, Managing Director and Group Chief Executive Officer commented on the result: “Telix has delivered an excellent result across all key financial metrics. The business has demonstrated its ability to commercialise successfully, delivering an impressive $218.3M in total revenue from Illuccix sales [14] in H1 2023, with sustained growth in demand since launch.
“Importantly, Telix has transitioned to positive earnings on an adjusted EBITDAR basis signalling the profitability of our commercial organisation.
“We have a positive outlook for continued growth in commercial sales of Illuccix, based on an expanding global PSMA PET imaging market, and expect to see Telix launch two new products in 2024 for brain and kidney cancer imaging, subject to regulatory approval.
“The business is making great progress across its therapeutic programs and, with a number of exciting clinical milestones ahead, will further demonstrate the value and differentiation of its industry-leading pipeline.”
Investor Call
An investor webcast will be held at 8.30am AEST on Thursday 24 August 2023 (6.30pm EDT, Wednesday 23 August 2023) Participants can register for the webcast and find audio call details at the following link: https://edge.media-server.com/mmc/p/2sr9bunm
To view the full Results Announcement click here
To view the Appendix 4D and 2023 Interim Report click here
To view the accompanying H1 2023 Results Presentation click here
[1] Conversion to AUD$ is at the actual exchange rate on transaction date. The average exchange rate realised during the period of AUD$1 = US$0.67; AUD$1 = €0.62.
[2] Prostate-specific membrane antigen.
[3] Telix ASX disclosure 16 March 2023. Illuccix is now approved for use for the selection of patients with metastatic prostate cancer, for whom lutetium-177 ( 177 Lu) PSMA-directed therapy is indicated, specifically lutetium Lu 177 vipivotide tetraxetan PSMA-directed therapy, marketed as Pluvicto® (Pluvicto is a registered trademark of Novartis AG and/or its affiliates).
[4] Telix ASX disclosure 19 July 2023.
[5] Telix ASX disclosure 19 June 2023.
[6] Telix media release 19 July 2023.
[7] Telix media release 8 August 2023.
[8] Telix ASX disclosure 11 August 2023.
[9] Telix ASX disclosure 19 July 2023.
[10] Telix media release 11 April 2023.
[11] Telix media release 8 June 2023.
[12] Telix ASX disclosure 21 June 2023. Subject to completion.
[13] Telix ASX disclosure 27 April 2023.
[14] Includes pre-commercial sales from investigational, clinical trial, magisterial and compassionate use in accordance with local laws and regulations (not as a commercial diagnostic imaging product sold for routine clinical practice).